Progressive kidney disease is characterized by accumulation of extracellular matrix (ECM) in glomeruli and tubulointerstitium leading to loss of kidney function and kidney failure regardless of the underlying disorder. Slowing or stopping this ECM build-up is the biggest challenge facing nephrologists today. Th us a major eff ort has been the analysis of mechanisms involved in the pathogenesis of chronic renal fi brosis. Th rough understanding of these mechanisms, it might be possible to prevent the development of progressive renal insuffi ciency, thus minimizing the clinical, social, and economic impact of endstage renal disease.
Th e studies of Brenner and colleagues (reviewed by Neuringer and Brenner 1 ) were an early systematic analysis of factors that underlie the progression of renal disease. Th ese studies demonstrated that hyperfiltration and increased intraglomerular pressure caused a progressive decrease of glomerular fi ltration, resulting in complete organ failure. Th en, in 1990, three papers by Border et al. (reviewed by Border and Noble 2 ) suggested that TGFβ overexpression was a key mediator of fi brotic renal disease. As shown in Figure  1 , this area of research has grown exponentially, so that now therapeutic targeting of TGFβ overexpression holds much hope for slowing or halting pathological ECM accumulation. Th e profi brotic actions of TGFβ include stimulation of ECM synthesis, inhibition of ECM degradation, and modulation of ECM receptor expression to facilitate cell-ECM interaction. Over a period of years, TGFβ overexpression has been shown to be a component of virtually every fi brotic disease in both humans and animal models. Additional basic research uncovered the existence of TGFβ isoforms and identifi ed mechanisms of TGFβ activation and TGFβ signaling at the level of extracellular ligand activation and intracellular signal transduction. Th e identifi cation of the regulation and dysregulation of postreceptor signaling shed new light on the pathways by which TGFβ contributes to fi brotic kidney disease, as Fukasawa et al. 3 show in this issue.
But fi rst, some background. TGFβ is synthesized as an inactive precursor containing an amino-terminal prodomain. Th e prodomain, also termed latency-associated protein, is cleaved within the Golgi apparatus but remains non-covalently bound to TGFβ, thereby preventing TGFβ from binding to its receptors. Th is latent complex of TGFβ and latency-associated protein also associates with latent TGFβ-binding proteins before secretion from the cell. Aft er secretion, most TGFβ is stored in the ECM as part of this inactive complex with latency-associated protein and latent TGFβ-binding proteins. Th e latent TGFβ complex can be activated into mature, biologically active TGFβ through the actions of proteases, such as plasmin, or by thrombospondin-1. Aft er release from the latent complex, TGFβ dimers initiate their cellular effects by binding to cell membrane receptors. Th ree TGFβ receptors are involved in TGFβ signal transduction. TGFβ first binds to the type III TGFβ receptor, which then presents the ligand to the type II receptor or directly binds to the type II receptor. Th e type I receptor subsequently is recruited to form a stable receptor complex consisting of two receptors of each type, allowing phosphorylation of the glycine/serine-rich sequences by the type II receptor kinases. Th is phosphorylation activates the type I receptor kinases, resulting in autophosphorylation of the type I receptor and phosphorylation of certain members of the Smad family of signal-transducing proteins. Smad2 and Smad3 phosphorylated by the type I receptor homodimerize and then bind to Smad4. Th e heteromeric complex of Smad2 or Smad3 and Smad4 translocates to the nucleus, where it regulates the transcription of target genes. 4 Smad4 therefore seems to be critical for the Smad signaling pathway. Studies have shown that defi ciency of Smad4 prevents TGFβ-induced collagen but not fi bronectin expression, demonstrating that both Smad-dependent and Smad-independent signaling pathways mediate TGFβ-induced ECM overexpression. 5 With the use of mouse embryo fi broblasts isolated from either Smad3 or Smad2 knockout (KO) mice, TGFβ-induced collagen type I and type III expression was ablated in Smad3 KO fibroblasts, but not in Smad2 KO fi bro blasts. 6 A 900-gene chip microarray analy sis further indicated that Smad3 is an essential mediator of TGFβ signaling. 7 In db/db mice, a genetic model of type 2 diabetes, compared with control mice, increased nuclear localization of Smad3 in glomerular and tubular cells commentar y and increased binding of nuclear proteins to the Smad-binding element were seen. 8 Similar increases in nuclear localization of Smad3 and activation of the Smad-binding element were observed in kidneys of mice with streptozotocininduced (type 1) diabetes, and these increases were prevented by administration of TGFβ-neutralizing antibodies. When Smad3 KO mice were treated with streptozotocin, diabetes-induced thickening of glomerular basement membrane, albuminuria, and upregulation of fi bronectin and collagen IV expression were attenuated, which suggests that local activation of Smad3 is important in the development of diabetic nephropathy. 9 In unilateral ureteral obstruction, upregulation of TGFβ is thought to induce epithelial-mesenchymal transition of renal tubules that then go on to deposit ECM. Aft er unilateral ureteral obstruction, Smad3 KO mice were protected from tubulointerstitial fibrosis, as evidenced by blocking of epithelialmesenchymal transition and decreased monocyte infl ux and collagen accumulation. Primary cultures of renal tubular epithelial cells from Smad3 wild-type mice underwent epithelial-mesenchymal transition aft er TGFβ treatment, as evidenced by loss of E-cadherin expression, induction of α-smooth muscle cell actin expression, and induction of the expression of Snail (a potent repressor of transcription of the E-cadherin gene), none of which occurred in cells prepared from Smad3 KO mice. 10 Th ese results provide clear evidence that activation of Smad3 mediates the profi brotic actions of TGFβ and is a critical feature of renal fi brosis. Three Smad transcriptional corepressors, namely Ski (Sloan-Kettering Institute proto-oncogene), SnoN (Ski-related novel gene, non-Alu-containing), and TGIF (TG-interacting factor), have been identified. 11 Once bound to corepressors, activated Smads form transcriptionally inactive complexes. Th e amount of transcriptional corepressor present within a cell in a given circumstance may determine the ultimate outcome of a TGFβ response.
In their new paper, Fukasawa et al. 3 demonstrate a dramatic reduction of the Smad transcriptional corepressors Ski and SnoN at the protein level in the fi brotic kidney aft er obstructive injury. Because SnoN and Ski function as Smad transcriptional antagonists, their loss represents elimination of a crucial negative control mechanism for TGFβ action, potentially leading to unrestrained TGFβ signal transduction in the kidney under pathological conditions. The authors also show that SnoN and Ski proteins are reduced not by decreases in their mRNA expression but by accelerated degradation involving the ubiquitin-proteasome pathway. Th ese results strongly suggest that loss of Smad corepressors is an important mechanism that amplifies profibrotic TGFβ signaling in this model. It remains to be seen whether the downregulation 
